SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 30, 2000
Diacrin Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-20139 22-3016912
-------------------------- ------------------- --------------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
Building 96, 13th Street
Charlestown Navy Yard
Charlestown, MA 02129
------------------------------------ -----------------------------------
(Address of principal executive (Zip Code)
offices)
Registrant's telephone number, including area code:
(617) 242-9100
N/A
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events.
The press release issued by Genzyme Corporation attached hereto as
Exhibit 99.1 is incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and
Exhibits.
(c) Exhibits.
See Exhibit Index attached hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: June 30, 2000 DIACRN INC.
By: /s/ Thomas H. Fraser
---------------------------
Thomas H. Fraser, Ph.D.
Chief Executive Officer
EXHIBIT INDEX
Exhibit
No. Description
------ ------------------
99.1 Press Release dated June 29, 2000 issued
by Genzyme Corporation
